2026-10-13T16:32:46Z https://api.figshare.com/v2/oai

oai:figshare.com:article/33998326 2026-09-25T17:29:20Z category_4 category_8 category_12 category_13 category_19 category_21 category_46 category_64 category_128 category_132 category_135 portal_5 item_type_3 month_year_09_2026

<p>Exploratory comparisons (ANOVA) of trough levels of IgG subclasses 1‑4 at steady state to assess the equivalence of BT595 and previous reference immunoglobulin – PK trough set.</p> Fabian Bohländer (10953165) Silke Aigner (14975881) Joachim Schütze (25111225) Jörg Schüttrumpf (308934) Christiane Staiger (25111228) Biochemistry Microbiology Cell Biology Genetics Pharmacology Biotechnology Immunology Cancer Hematology Infectious Diseases Computational Biology numerically prolonged persistence approximately 12 months multicenter clinical trial published ivig data div >< p licensed ivig products steady state prior q4w dosing due ivig replacement therapy patients received bt595 replacement therapy ivig products trial 991 steady state q4w dosing dosing regimens dosing interval whereas igg3 trough concentrations total igg shorter interval q4w ). primary immunodeficiency pharmacokinetic profiles pharmacokinetic parameters mean concentrations lower compared intravenous immunoglobulin indicating preservation igg subclasses estimated half endogenous igg age categories <p>Exploratory comparisons (ANOVA) of trough levels of IgG subclasses 1‑4 at steady state to assess the equivalence of BT595 and previous reference immunoglobulin – PK trough set.</p> 2026-09-25T17:29:11Z Dataset Dataset 10.1371/journal.pone.0357472.t002 https://figshare.com/articles/dataset/_p_Exploratory_comparisons_ANOVA_of_trough_levels_of_IgG_subclasses_1_4_at_steady_state_to_assess_the_equivalence_of_BT595_and_previous_reference_immunoglobulin_PK_trough_set_p_/33998326 CC BY 4.0